Viking Thera Cmn (VKTX) 1.28 $VKTX Viking Thera
Post# of 273242
Posted On: 09/19/2016 5:13:46 PM
Viking Thera Cmn (VKTX) 1.28 $VKTX
Viking Therapeutics to Present at Upcoming Investor Conferences
PR Newswire - Wed Sep 07, 6:00AM CDT
Viking Therapeutics, Inc. ("Viking"
(NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at two upcoming investor conferences in New York, NY. Dr. Lian will present at the Rodman & Renshaw 18th Annual Global Investment Conference, being held September 11-13, 2016, and the Ladenburg Thalmann 2016 Healthcare Conference, being held on September 27, 2016.
VKTX: 1.28 (unch)
Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
PR Newswire - Thu Sep 01, 6:30AM CDT
Viking Therapeutics, Inc. ("Viking" (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of data from a Phase 1 trial of VK5211, the company's lead program for muscle and bone disorders, at the 5th Fragility Fracture Network (FFN) Global Congress 2016, currently underway in Rome, Italy. The results of this study showed VK5211 to be safe, well tolerated, and to have a predictable pharmacokinetic (PK) profile in healthy women and men age 65 and over. Also during the conference, the company will make an oral presentation highlighting its ongoing Phase 2 study of VK5211 in patients recovering from non-elective hip fracture surgery. FFN organizers have designated Viking's VK5211 Phase 2 study design as one of the conference's top 15 poster presentations and will feature it as part of an oral plenary poster presentation session on September 2.
VKTX: 1.28 (unch)
Viking Therapeutics Enters Into $12.5 Million Common Stock Purchase Agreement with Aspire Capital
PR Newswire - Thu Aug 25, 6:30AM CDT
Viking Therapeutics, Inc. ("Viking" (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced it has entered into a $12.5 million common stock purchase agreement with Aspire Capital Fund, LLC ("Aspire Capital" .
VKTX: 1.28 (unch)
Viking Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Wed Aug 10, 6:05AM CDT
Viking Therapeutics, Inc. ("Viking" (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter of 2016, and provided an update on its clinical pipeline and other corporate developments.
VKTX: 1.28 (unch)
Viking Therapeutics to Present at the 2016 Marcum Microcap Conference
PR Newswire - Tue May 24, 3:15PM CDT
Viking Therapeutics, Inc. ("Viking" (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 2016 Marcum Microcap Conference, being held June 1-2, 2016 in New York City.
VKTX: 1.28 (unch)
Viking Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Tue May 10, 3:01PM CDT
Viking Therapeutics, Inc. ("Viking" (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced financial results for the first quarter of 2016, and provided an update on its clinical pipeline and other corporate developments.
VKTX: 1.28 (unch)
Viking Therapeutics Announces Full Exercise of Over-Allotment Option
PR Newswire - Mon May 02, 6:30AM CDT
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that the underwriters of Viking's public offering that initially closed on April 13, 2016 have purchased an additional 1,125,000 shares of Viking's common stock at a price of $1.24 per share, before deducting the underwriting discount, in connection with the exercise of their over-allotment option (the "Over-Allotment Option" , which has now been exercised in full. Viking received additional gross proceeds of approximately $1.4 million from the exercise of the Over-Allotment Option, increasing the aggregate gross proceeds to Viking from the offering to approximately $10.8 million, before deducting offering expenses, underwriting discounts and commissions payable by Viking.
VKTX: 1.28 (unch)
Viking Therapeutics Announces Closing of Public Offering of Common Stock and Warrants
PR Newswire - Wed Apr 13, 4:00PM CDT
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the closing of its previously-announced underwritten public offering of 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of $1.25 per share of common stock and related warrant. The warrants have an exercise price of $1.50 per share of common stock, are immediately exercisable and will expire on April 13, 2021.
VKTX: 1.28 (unch)
Viking Therapeutics Presents Positive Phase 1b Clinical Data on VK2809 in Hypercholesterolemic Subjects
PR Newswire - Mon Apr 11, 6:30AM CDT
Viking Therapeutics, Inc. ("Viking" (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today highlighted positive data from a Phase 1b clinical trial of VK2809 in subjects with mild hypercholesterolemia, presented at the 65th Annual Scientific Session & Expo of the American College of Cardiology (ACC). The results demonstrated substantial and clinically meaningful reductions in subjects' low-density lipoprotein cholesterol (LDL-C), triglycerides, and atherogenic proteins lipoprotein-a and apolipoprotein B following 14 days of treatment. VK2809 is a novel, orally available small molecule thyroid receptor agonist that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promising therapeutic potential in this patient population.
VKTX: 1.28 (unch)
Viking Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
PR Newswire - Fri Apr 08, 7:30AM CDT
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of $1.25 per share of common stock and related warrant, for total expected gross proceeds to Viking of approximately $9,375,000, before deducting underwriting discounts, commissions, and other offering expenses. The warrants have an exercise price of $1.50 per share of common stock, are exercisable immediately and will expire five years from the date of issuance. Additionally, Viking has granted the underwriters a 45-day option to purchase up to an additional 1,125,000 shares of its common stock and/or warrants to purchase up to an additional 1,125,000 shares of its common stock to cover over-allotments, if any. All of the shares of common stock and warrants are being offered by Viking.
VKTX: 1.28 (unch)
Hypercholesterolemia - Pipeline Review H2 2015
M2 - Fri Jan 22, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/dmg5h6/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hypercholesterolemia Overview - Therapeutics Development - Pipeline Products for Hypercholesterolemia - Overview - Pipeline Products for Hypercholesterolemia - Comparative Analysis - Hypercholesterolemia - Therapeutics under Development by Companies - Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes - Hypercholesterolemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypercholesterolemia - Products under Development by Companies - Hypercholesterolemia - Products under Investigation by Universities/Institutes - Hypercholesterolemia - Companies Involved in Therapeutics Development - 3SBio Inc. - Abeome Corporation - Aegerion Pharmaceuticals, Inc. - Amgen Inc. - AtheroNova Inc. - BioLingus AG - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - CymaBay Therapeutics, Inc. - Daewon Pharm Co. Ltd. - DreamPharma Corp. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Gemphire Therapeutics Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Immune Response BioPharma, Inc. - Johnson & Johnson - Kadmon Corporation, LLC - Kowa Company, Ltd. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - Sanofi - Serometrix, LLC - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - The Medicines Company - Thetis Pharmaceuticals LLC - Viking Therapeutics, Inc. - Zhejiang Hisun Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/dm...lesterolem
JNJ: 117.66 (-0.59), ESPR: 11.44 (+0.22), PFE: 33.65 (-0.29), MRK: 61.33 (-0.95), CBAY: 1.98 (-0.01), AMGN: 171.38 (-1.58), LLY: 79.16 (+0.36), AEGR: 1.86 (+0.08), VKTX: 1.28 (unch), REGN: 402.83 (-5.80), NVS: 79.94 (+0.60)
Viking Therapeutics to Present at Biotech Showcase 2016
PR Newswire - Thu Jan 07, 6:30AM CST
Viking Therapeutics, Inc. ("Viking" (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 8th Annual Biotech Showcase(TM), being held January 11-13, 2016 in San Francisco.
VKTX: 1.28 (unch)
Bone Fracture - Pipeline Review 2015
M2 - Wed Jan 06, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/nh5zfn/bone_fracture) has announced the addition of the "Bone Fracture - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Fracture and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Bone Fracture. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Arcarios BV - AstraZeneca Plc - Biogenomics Limited - Biopharm GmbH - Bone Therapeutics SA - Juventas Therapeutics, Inc. - Kaken Pharmaceutical Co., Ltd. - Kolon Life Science, Inc. - Kuros Biosurgery AG - Novartis AG - OrgaNext Research BV - TissueGene, Inc. - Viking Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/nh...e_fracture
AZN: 33.52 (-0.30), VKTX: 1.28 (unch), NVS: 79.94 (+0.60)
Valeant and Freeport-McMoRan are big market movers
AP - Mon Dec 28, 4:37PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:
ICON: 8.07 (+0.12), VRX: 27.10 (-0.18), DNOW: 19.04 (-0.06), CHK: 6.81 (-0.54), VKTX: 1.28 (unch), VRX.TO: 35.82 (-0.27)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gd4hqf/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Aquinox Pharmaceuticals Inc. - Ardelyx, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Connexios Life Sciences Pvt. Ltd. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - DURECT Corporation - Dynavax Technologies Corporation - Enanta Pharmaceuticals, Inc. - Exicure, Inc. - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - iCo Therapeutics Inc. - Merck & Co., Inc. - Mochida Pharmaceutical Co., Ltd. - NGM Biopharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Novartis AG - Novo Nordisk A/S - Protalix BioTherapeutics, Inc. - Regulus Therapeutics Inc. - RuiYi Inc. - Shire Plc - Vascular Biogenics Ltd. - Verva Pharmaceuticals Limited - Viking Therapeutics, Inc. - Virobay Inc. - Zafgen Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/gd...nalcoholic
DVAX: 12.11 (+0.16), ZFGN: 3.14 (unch), AQXP: 12.68 (-0.71), GALT: 1.67 (-0.03), RGLS: 3.28 (+0.05), BMY: 55.08 (-0.52), DRRX: 1.68 (+0.04), ENTA: 25.65 (+0.82), NVO: 45.73 (-0.39), GILD: 78.99 (+0.19), SHPG: 203.44 (+2.84), MRK: 61.33 (-0.95), VBAY: (), VBLT: 4.54 (-0.17), VKTX: 1.28 (unch), NVS: 79.94 (+0.60)
Bone Fracture Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Opportunities
M2 - Fri Dec 11, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/wkqvmp/bone_fracture) has announced the addition of the "Bone Fracture Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report, Bone Fracture Global Clinical Trials Review, H2, 2015" provides an overview of Bone Fracture clinical trials scenario. This report provides top line data relating to the clinical trials on Bone Fracture. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Pfizer Inc. - Viking Therapeutics, Inc. - Amgen Inc. - Ono Pharmaceutical Co., Ltd. - Novo A/S - Novartis AG - Bone Therapeutics SA - AstraZeneca Plc - Astellas Pharma Inc. - Amorphical Ltd. For more information visit http://www.researchandmarkets.com/research/wk...e_fracture
PFE: 33.65 (-0.29), AZN: 33.52 (-0.30), AMGN: 171.38 (-1.58), VKTX: 1.28 (unch), NVS: 79.94 (+0.60)
Nonalcoholic Steatohepatitis (NASH) Commercial Opportunities - Pipeline Analysis & Forecast Report
M2 - Mon Dec 07, 8:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/p3853f/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. NASH Facts: - 10% of the adult population in U.S has NASH - NASH can occur in all age groups and even in children but mostly it is diagnosed in the patients between the age of 40-60 - NASH affects between 9.5-16 million people in United States accounting for 3 to 5 % of the population - NASH is a third leading and rapidly increasing indication for liver transplants accounting for 10% of liver transplants in U.S. - In America, the obesity rate has doubled in adults and tripled in children in the past 10 years which would impact the prevalence of NASH in the coming years, being one of the major risk factors for NASH - NASH has the potential to become one of the leading cause of end stage liver disease, liver transplantation, and hepatocellular carcinoma in the next decades This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Companies Mentioned: - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics Report Structure: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players 15. References For more information visit http://www.researchandmarkets.com/research/p3...nalcoholic
GILD: 78.99 (+0.19), VKTX: 1.28 (unch)
Viking Therapeutics to Present at Upcoming Investor Conferences
PR Newswire - Wed Sep 07, 6:00AM CDT
Viking Therapeutics, Inc. ("Viking"
(NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at two upcoming investor conferences in New York, NY. Dr. Lian will present at the Rodman & Renshaw 18th Annual Global Investment Conference, being held September 11-13, 2016, and the Ladenburg Thalmann 2016 Healthcare Conference, being held on September 27, 2016. VKTX: 1.28 (unch)
Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
PR Newswire - Thu Sep 01, 6:30AM CDT
Viking Therapeutics, Inc. ("Viking"
(NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of data from a Phase 1 trial of VK5211, the company's lead program for muscle and bone disorders, at the 5th Fragility Fracture Network (FFN) Global Congress 2016, currently underway in Rome, Italy. The results of this study showed VK5211 to be safe, well tolerated, and to have a predictable pharmacokinetic (PK) profile in healthy women and men age 65 and over. Also during the conference, the company will make an oral presentation highlighting its ongoing Phase 2 study of VK5211 in patients recovering from non-elective hip fracture surgery. FFN organizers have designated Viking's VK5211 Phase 2 study design as one of the conference's top 15 poster presentations and will feature it as part of an oral plenary poster presentation session on September 2. VKTX: 1.28 (unch)
Viking Therapeutics Enters Into $12.5 Million Common Stock Purchase Agreement with Aspire Capital
PR Newswire - Thu Aug 25, 6:30AM CDT
Viking Therapeutics, Inc. ("Viking"
(NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced it has entered into a $12.5 million common stock purchase agreement with Aspire Capital Fund, LLC ("Aspire Capital" . VKTX: 1.28 (unch)
Viking Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Wed Aug 10, 6:05AM CDT
Viking Therapeutics, Inc. ("Viking"
(NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter of 2016, and provided an update on its clinical pipeline and other corporate developments. VKTX: 1.28 (unch)
Viking Therapeutics to Present at the 2016 Marcum Microcap Conference
PR Newswire - Tue May 24, 3:15PM CDT
Viking Therapeutics, Inc. ("Viking"
(NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 2016 Marcum Microcap Conference, being held June 1-2, 2016 in New York City. VKTX: 1.28 (unch)
Viking Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Tue May 10, 3:01PM CDT
Viking Therapeutics, Inc. ("Viking"
(NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced financial results for the first quarter of 2016, and provided an update on its clinical pipeline and other corporate developments. VKTX: 1.28 (unch)
Viking Therapeutics Announces Full Exercise of Over-Allotment Option
PR Newswire - Mon May 02, 6:30AM CDT
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that the underwriters of Viking's public offering that initially closed on April 13, 2016 have purchased an additional 1,125,000 shares of Viking's common stock at a price of $1.24 per share, before deducting the underwriting discount, in connection with the exercise of their over-allotment option (the "Over-Allotment Option"
, which has now been exercised in full. Viking received additional gross proceeds of approximately $1.4 million from the exercise of the Over-Allotment Option, increasing the aggregate gross proceeds to Viking from the offering to approximately $10.8 million, before deducting offering expenses, underwriting discounts and commissions payable by Viking. VKTX: 1.28 (unch)
Viking Therapeutics Announces Closing of Public Offering of Common Stock and Warrants
PR Newswire - Wed Apr 13, 4:00PM CDT
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the closing of its previously-announced underwritten public offering of 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of $1.25 per share of common stock and related warrant. The warrants have an exercise price of $1.50 per share of common stock, are immediately exercisable and will expire on April 13, 2021.
VKTX: 1.28 (unch)
Viking Therapeutics Presents Positive Phase 1b Clinical Data on VK2809 in Hypercholesterolemic Subjects
PR Newswire - Mon Apr 11, 6:30AM CDT
Viking Therapeutics, Inc. ("Viking"
(NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today highlighted positive data from a Phase 1b clinical trial of VK2809 in subjects with mild hypercholesterolemia, presented at the 65th Annual Scientific Session & Expo of the American College of Cardiology (ACC). The results demonstrated substantial and clinically meaningful reductions in subjects' low-density lipoprotein cholesterol (LDL-C), triglycerides, and atherogenic proteins lipoprotein-a and apolipoprotein B following 14 days of treatment. VK2809 is a novel, orally available small molecule thyroid receptor agonist that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promising therapeutic potential in this patient population. VKTX: 1.28 (unch)
Viking Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
PR Newswire - Fri Apr 08, 7:30AM CDT
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of $1.25 per share of common stock and related warrant, for total expected gross proceeds to Viking of approximately $9,375,000, before deducting underwriting discounts, commissions, and other offering expenses. The warrants have an exercise price of $1.50 per share of common stock, are exercisable immediately and will expire five years from the date of issuance. Additionally, Viking has granted the underwriters a 45-day option to purchase up to an additional 1,125,000 shares of its common stock and/or warrants to purchase up to an additional 1,125,000 shares of its common stock to cover over-allotments, if any. All of the shares of common stock and warrants are being offered by Viking.
VKTX: 1.28 (unch)
Hypercholesterolemia - Pipeline Review H2 2015
M2 - Fri Jan 22, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/dmg5h6/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hypercholesterolemia Overview - Therapeutics Development - Pipeline Products for Hypercholesterolemia - Overview - Pipeline Products for Hypercholesterolemia - Comparative Analysis - Hypercholesterolemia - Therapeutics under Development by Companies - Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes - Hypercholesterolemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypercholesterolemia - Products under Development by Companies - Hypercholesterolemia - Products under Investigation by Universities/Institutes - Hypercholesterolemia - Companies Involved in Therapeutics Development - 3SBio Inc. - Abeome Corporation - Aegerion Pharmaceuticals, Inc. - Amgen Inc. - AtheroNova Inc. - BioLingus AG - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - CymaBay Therapeutics, Inc. - Daewon Pharm Co. Ltd. - DreamPharma Corp. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Gemphire Therapeutics Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Immune Response BioPharma, Inc. - Johnson & Johnson - Kadmon Corporation, LLC - Kowa Company, Ltd. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - Sanofi - Serometrix, LLC - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - The Medicines Company - Thetis Pharmaceuticals LLC - Viking Therapeutics, Inc. - Zhejiang Hisun Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/dm...lesterolem
JNJ: 117.66 (-0.59), ESPR: 11.44 (+0.22), PFE: 33.65 (-0.29), MRK: 61.33 (-0.95), CBAY: 1.98 (-0.01), AMGN: 171.38 (-1.58), LLY: 79.16 (+0.36), AEGR: 1.86 (+0.08), VKTX: 1.28 (unch), REGN: 402.83 (-5.80), NVS: 79.94 (+0.60)
Viking Therapeutics to Present at Biotech Showcase 2016
PR Newswire - Thu Jan 07, 6:30AM CST
Viking Therapeutics, Inc. ("Viking"
(NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 8th Annual Biotech Showcase(TM), being held January 11-13, 2016 in San Francisco. VKTX: 1.28 (unch)
Bone Fracture - Pipeline Review 2015
M2 - Wed Jan 06, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/nh5zfn/bone_fracture) has announced the addition of the "Bone Fracture - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Fracture and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Bone Fracture. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Arcarios BV - AstraZeneca Plc - Biogenomics Limited - Biopharm GmbH - Bone Therapeutics SA - Juventas Therapeutics, Inc. - Kaken Pharmaceutical Co., Ltd. - Kolon Life Science, Inc. - Kuros Biosurgery AG - Novartis AG - OrgaNext Research BV - TissueGene, Inc. - Viking Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/nh...e_fracture
AZN: 33.52 (-0.30), VKTX: 1.28 (unch), NVS: 79.94 (+0.60)
Valeant and Freeport-McMoRan are big market movers
AP - Mon Dec 28, 4:37PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq stock market:
ICON: 8.07 (+0.12), VRX: 27.10 (-0.18), DNOW: 19.04 (-0.06), CHK: 6.81 (-0.54), VKTX: 1.28 (unch), VRX.TO: 35.82 (-0.27)
Non-Alcoholic Steatohepatitis Therapeutics Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/gd4hqf/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Aquinox Pharmaceuticals Inc. - Ardelyx, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Connexios Life Sciences Pvt. Ltd. - Daiichi Sankyo Company, Limited - Dr. Falk Pharma GmbH - DURECT Corporation - Dynavax Technologies Corporation - Enanta Pharmaceuticals, Inc. - Exicure, Inc. - Galectin Therapeutics, Inc. - Galmed International Ltd. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - iCo Therapeutics Inc. - Merck & Co., Inc. - Mochida Pharmaceutical Co., Ltd. - NGM Biopharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nippon Chemiphar Co., Ltd. - Novartis AG - Novo Nordisk A/S - Protalix BioTherapeutics, Inc. - Regulus Therapeutics Inc. - RuiYi Inc. - Shire Plc - Vascular Biogenics Ltd. - Verva Pharmaceuticals Limited - Viking Therapeutics, Inc. - Virobay Inc. - Zafgen Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/gd...nalcoholic
DVAX: 12.11 (+0.16), ZFGN: 3.14 (unch), AQXP: 12.68 (-0.71), GALT: 1.67 (-0.03), RGLS: 3.28 (+0.05), BMY: 55.08 (-0.52), DRRX: 1.68 (+0.04), ENTA: 25.65 (+0.82), NVO: 45.73 (-0.39), GILD: 78.99 (+0.19), SHPG: 203.44 (+2.84), MRK: 61.33 (-0.95), VBAY: (), VBLT: 4.54 (-0.17), VKTX: 1.28 (unch), NVS: 79.94 (+0.60)
Bone Fracture Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Opportunities
M2 - Fri Dec 11, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/wkqvmp/bone_fracture) has announced the addition of the "Bone Fracture Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report, Bone Fracture Global Clinical Trials Review, H2, 2015" provides an overview of Bone Fracture clinical trials scenario. This report provides top line data relating to the clinical trials on Bone Fracture. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Pfizer Inc. - Viking Therapeutics, Inc. - Amgen Inc. - Ono Pharmaceutical Co., Ltd. - Novo A/S - Novartis AG - Bone Therapeutics SA - AstraZeneca Plc - Astellas Pharma Inc. - Amorphical Ltd. For more information visit http://www.researchandmarkets.com/research/wk...e_fracture
PFE: 33.65 (-0.29), AZN: 33.52 (-0.30), AMGN: 171.38 (-1.58), VKTX: 1.28 (unch), NVS: 79.94 (+0.60)
Nonalcoholic Steatohepatitis (NASH) Commercial Opportunities - Pipeline Analysis & Forecast Report
M2 - Mon Dec 07, 8:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/p3853f/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. NASH Facts: - 10% of the adult population in U.S has NASH - NASH can occur in all age groups and even in children but mostly it is diagnosed in the patients between the age of 40-60 - NASH affects between 9.5-16 million people in United States accounting for 3 to 5 % of the population - NASH is a third leading and rapidly increasing indication for liver transplants accounting for 10% of liver transplants in U.S. - In America, the obesity rate has doubled in adults and tripled in children in the past 10 years which would impact the prevalence of NASH in the coming years, being one of the major risk factors for NASH - NASH has the potential to become one of the leading cause of end stage liver disease, liver transplantation, and hepatocellular carcinoma in the next decades This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Companies Mentioned: - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics Report Structure: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players 15. References For more information visit http://www.researchandmarkets.com/research/p3...nalcoholic
GILD: 78.99 (+0.19), VKTX: 1.28 (unch)
(0)
(0)Scroll down for more posts ▼